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Fernando Ezquer,1 Marcelo Ezquer,1,2 Valeska Simon,1 Fabian Pardo,3 Alejandro Yan˜ez,3
Daniel Carpio,4 Paulette Conget1Twenty-five to 40% of diabetic patients develop diabetic nephropathy, a clinical syndrome that comprises
renal failure and increased risk of cardiovascular disease. It represents the major cause of chronic kidney dis-
ease and is associated with premature morbimortality of diabetic patients. Multipotent mesenchymal stromal
cells (MSC) contribute to the regeneration of several organs, including acutely injured kidney. We sought to
evaluate if MSC protect kidney function and structure when endovenously administered to mice with severe
diabetes. A month after nonimmunologic diabetes induction by streptozotocin injection, C57BL/6 mice pre-
sented hyperglycemia, glycosuria, hypoinsulinemia, massive b-pancreatic islet destruction, low albuminuria,
but not renal histopathologic changes (DM mice). At this stage, one group of animals received the vehicle
(untreated) and other group received 2 doses of 0.5106 MSC/each (MSC-treated). Untreated DM mice
gradually increased urinary albumin excretion and 4 months after diabetes onset, they reached values 15
times higher than normal animals. In contrast, MSC-treated DM mice maintained basal levels of albuminuria.
Untreated DMmice had marked glomerular and tubular histopathologic changes (sclerosis, mesangial expan-
sion, tubular dilatation, proteins cylinders, podocytes lost). However, MSC-treated mice showed only slight
tubular dilatation. Observed renoprotection was not associated with an improvement in endocrine pancreas
function in this animal model, because MSC-treated DM mice remained hyperglycemic and hypoinsulinemic,
and maintained few remnant b-pancreatic islets throughout the study period. To study MSC biodistribution,
cells were isolated from isogenic mice that constitutively express GFP (MSCGFP) and endovenously admin-
istered to DMmice. Although at very low levels, donor cells were found in kidney of DM mice 3 month after
transplantation. Presented preclinical results support MSC administration as a cell therapy strategy to pre-
vent chronic renal diseases secondary to diabetes.
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Diabetes mellitus (DM) is one of the current main
threats to public health [1]. According to the World
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the year 2000 to 366 million in 2030 [2]. About 25%
to 40% of diabetic patients, within 20 to 25 years of
the onset of type 1 or type 2 DM, will develop diabetic
nephropathy (DN). A clinical syndrome that com-
prises renal failure and increased risk of cardiovascular
disease [3]. DN represents the major cause of chronic
kidney disease [4]. Thus, it is one of the most detri-
mental long-term complications of DM, and is highly
associated with premature morbidity and mortality of
diabetic patients [5].
In susceptible patients, DN follows a well-known
temporal and clinical course. Microalbuminuria (low
level of albumin excretion in urine) is the earliest
detectable sign of kidney damage. It is associated
with histologic changes, which include glomerular
mesangial expansion, extracellular matrix deposition,
and glomerular basement membrane thickening [6].
Macroalbuminuria appears later on, followed by
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and marked histopathologic features. These include
arteriolar hyalinosis, glomeruloesclerosis, and tubu-
lointerstitial fibrosis [7,8]. At this stage, even if patients
were on dialysis, 21% of themwill die within a year [9].
In DN, the interaction of metabolic and hemody-
namic factors results in renal damage [8]. High
mitochondrial oxidative stress, generated by the aug-
mented glucose metabolism, leads to a reduction in
the number of glomerular podocytes [10-12]. Kidney-
activated macrophages maintain chronic inflammation
and produce interleukin (IL)-1, tumor necrosis factor
(TNF)-a, nitric oxide (NO), and reactive oxygen spe-
cies, resulting in increased vascular permeability and
renal cell death [13-15]. They also induce renal fibrosis
because of the secretion of fibroblast growth factor
(FGF) and transforming growth factor (TGF)-
b [15,16]. Thus, in DN, all the ultrafiltration compo-
nents (podocytes, fenestrated endothelial cells, and
glomerular basement membrane) are affected.
To date, there is no cure to DN. Patients’ manage-
ment comprises the use of drugs to control hyperglyce-
mia and blood pressure. If required, hemodialysis is
prescribed [17,18]. Unfortunately, those treatments
are very expensive, lifelong, and only helps to slow
DN progression [19].
Multipotent mesenchymal stromal cells (also
referred as mesenchymal stem cells [MSC]) are a popu-
lation of self-renewable and undifferentiated cells
present in the bone marrow (BM) and mesenchymal
tissues of adult individuals [20]. It has been proved
that MSC contribute to renal regeneration in animal
models of kidney injury. In drug-induced acute renal
failure, transplanted MSC engraft into the tubular
epithelium and promote the restoration of necrotic
segments [21,22]. MSC have also been successfully
used in the experimental treatment of severe kidney
diseases including glomerulonephropathy [23], and
Alport syndrome [24]. Together, we have demon-
strated that systemic administration of MSC into
immunologically induced type 1 diabetic mice reduced
microalbuminuria and preserved normal renal
histology. By contrast, untreated type 1 diabetic mice
were microalbuminuric and presented glomerular
hyalinosis and mesangial expansion [25]. Observed
renoprotection was associated with the concomitant
improvement of diabetes condition because of the re-
generation of insulin-producing cells and restriction
of glucagon-producing cells. On the other hand, in
an incomplete model of type 2 DM settled in immuno-
deficient nonobese diabetic (NOD)/severe combined
immunodeficiency (SCID) mice, an intracardiac infu-
sion of a large number of human MSC (250106/
kg body weight) resulted in the homing of donor cells
into the kidneys. Unfortunately, it is not known
whether this had any functional consequence, as
animals did not present renal failure before theintervention or during the follow-up period [26].
Thus, data already published suggest that MSC ad-
ministration might be renoprotective in diabetic indi-
viduals. However, animal models previously used to
test this only developed the earlier harbingers of DN
(mild microalbuminuria and tubular and glomerular
hyalinosis) [12,26]. Furthermore, it remains unknown
if renoprotection is secondary or not to the improve-
ment in endocrine pancreas function.
In the present work, we evaluated whether MSC
are renoproctective when endovenously administered
to nonimmunologically induced severe diabetic mice
that, despite not sharing the etiology of either type 1
or type 2DM, show a rapid progression of renal failure
and develop most of its pathognomonic signs [27-30].
For this, 30 days after the massive cytotoxic destruc-
tion of insulin-producing cells by the injection of a sin-
gle high dose of streptozotocin (STZ), C57BL/6 mice
were separated in 2 groups: one group received the ve-
hicle (untreated) and the other, 2 doses of 0.5106
MSC/each (MSC treated). Before the intervention,
and up to 90 days after it, kidney and pancreas function
and structure were assessed (Figure 1). Data obtained
for MSC-treated DM mice were compared against
diabetic untreated and normal nondiabetic mice.
Together, MSC biodistribution in severe nonimmu-
nologically induced diabetic mice was evaluated 7
and 90 days after systemic administration of MSC iso-
lated from isogenic mice that constitutively express
GFP (MSCGFP).MATERIALS AND METHODS
Animals
C57BL/6 andC57BL/6-Tg(ACTB-EGFP)1Osb/J
mice (Jackson Laboratory, Bar Harbor, ME) were
housed at constant temperature and humidity, with
a 12:12 h light-dark cycle and unrestricted access to
a standard diet and water. When required, animals
were lightly anesthetizedwith sevofluorane (Abbott, Ja-
pan). All animal protocols used were approved by the
EthicCommittee of Facultad deMedicina, Clinica Ale-
mana-Universidad del Desarrollo.Diabetes Induction
Eight-week-old male C57BL/6 mice were lightly
anesthetized and received intraperitoneally 200 mg/kg
STZ (Calbiochem, La Jolla, CA) immediately after
dissolving in 0.1 M citrate buffer at pH 4.5 (DM
mice) or citrate buffer only (normal mice). This proto-
col of STZ administration causes a massive cytotoxic
nonimmunologic destruction of insulin-producing
cells generating a severe hyperglycemia condition,
which accelerates the appearance of the secondary
complications associated to diabetes [31,32].
Figure 1. Protocol. To induce severe nonimmunologic diabetes, C57BL/6 adult male mice were injected with 200 mg/kg STZ (DM). Thirty and 51 days
after, animals received via the tail vein the vehicle (untreated) or 0.5106 MSC (MSC treated). During the follow-up period, urinary albumin excretion
was determined every 20 days and blood glucose level every 3 days, to monitor kidney and pancreas function, respectively. At day 120 postdiabetes
induction, kidney and pancreas structure were evaluated. Protocol was performed 3 times, and the total number of animals was 12 normal nondiabetic,
20 DM that received vehicle, and 20 DM that received MSC.
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Characterization
Eight- to 10 week-oldmale C57BL/6 or C57BL/6-
Tg(ACTB-EGFP)1Osb/J mice were sacrificed by
cervical dislocation. BM cells were obtained by flushing
femurs and tibias with sterile phosphate-buffered saline
(PBS). After centrifugation, cells were resuspended in
a-minimum essential medium (MEM) (Gibco, Auck-
land,NZ) supplementedwith 10% selected fetal bovine
serum (Gibco, Auckland,NZ) and 80mg/mL gentami-
cin (Sanderson Laboratory, Chile) and plated at a den-
sity of 1106 nucleated cells/cm2. Nonadherent cells
were removed after 72 hours by media change. When
foci reach confluence, adherent cells were detached
with 0.25% trypsin, 2.65 mM EDTA, centrifuged,
and subcultured at 7000 cells/cm2. After 2 subcultures,
adherent cellswere characterized according to their adi-
pogenic andosteogenicdifferentiationpotential, as pre-
viously described [33]. Although there is currently no
consensus markers for murine MSC as there is for hu-
man MSC [34], immunophenotyping was performed
by flow cytometry analysis after immunostaining with
monoclonal antibodies (mAbs) against putative murine
MSC markers: SCA-1 (APC-conjugated, eBioscience,
San Diego, CA) and CD90 (FITC-conjugated, eBio-
science) and hemopoietic lineage markers: B220,
CD4, CD8 (PE-Cy5-conjugated, BD Biosciences
Pharmingen, San Jose, CA) [35].MSC Administration
Thirty and 51 days postdiabetes induction 0.5106
MSC (or 0.5106 MSCGFP) were resuspended in 0.2
mL of 5% mice plasma and administered via the tail
vein to lightly anesthetized mice (MSC-treated DMmice). Untreated DM mice received 0.2 mL of 5%
mice plasma.
Blood Glucose Determination
From nonfasted alert animals, blood samples were
collected from the tail vein and glucose levels were
determined with the glucometer system Accu-Chek
Go from Roche Diagnostic (Mannheim, Germany).
Urinary Glucose Determination
Mice were kept in metabolic cages until they spon-
taneously urinated. Glucose levels were measured with
the glucometer system Accu-Chek Go. To fit samples
to the linear range of the glucometer system, urine was
diluted in 0.9% NaCl.
Plasma Insulin Determination
Plasma insulin was assayed on blood obtained from
the tail vein of fasted alert animals using a mouse-
specific ELISA kit (Ultrasensitive Mouse Insulin
ELISA; Mercodia, Uppsala, Sweden).
Urinary Albumin Determination
Excretion of urinary albuminwas determined using
albumin to creatinine ratio on morning spot urine col-
lections. Mice were kept in metabolic cages until they
spontaneously urinated. Urine albumin concentration
was determined using a human immunoturbidimetric
commercial kit from Orion Diagnostica (Espoo,
Finland). Previously, we proved that the antibodies in-
cluded in this kit crossreactwithmouse albumin [25], as
human and mouse albumins are 80% identical [36].
Urine creatinine concentration was determined by
the kinetic modified Jaffe method using a kit from
Applied Clinical Chemistry (Amposta, Spain) [25].
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Mice were anesthetized by intramuscular injection
of xylazine and ketamine and sacrificed by intracardiac
injection of thiopental. Kidneys and pancreas were
rapidly removed, fixed with 4% paraformaldehyde,
and embedded in paraffin. Renal sections (4 mm)
were stained with PAS reagent and 4-mm pancreatic
sections were stained with hematoxilin-eosin. Slices
were analyzed under light microscopy, focusing on
kidney glomeruli and tubules and pancreas islets, re-
spectively. Images were captured with a digital camera.
Renal biopsies were analyzed at the same time,
blinded, by the same specialized nephropathologist.
Extend of glomerular damage was expressed as the per-
centage of glomeruli presenting glomerulosclerosis or
mesangial expansion [37]. Tubular damage was graded,
from 0 to 4, according to the presence or not of dilata-
tion, proteins cylinders, and atrophy (05no changes,
15changes affecting\25% of the sample, 25changesFigure 2. Characterization of diabetes stage in mice that will be treated with
buffer (normal) or 200 mg/kg STZ in 0.1 M citrate buffer (DM). Thirty days af
samples obtained from alert nonfasted animals (A); glycosuria was determined
in venous blood samples obtained from alert fasted animals (C); urinary album
to albumin to creatinine concentration assessed by the use of commercial kits
observed under light microscopy and focusing on glomeruli and tubule struct
animals per experimental group. Qualitative data shown are representative of
nificant P values are shown.affecting 25% to 50% of the sample, 35changes affect-
ing 50% to 75% of the sample, and 45changes affect-
ing 75% to 100% of the sample) [37].Kidney Electron Microscopy Analysis
Kidneys were rapidly dissected out, and small
pieces of renal cortex were fixed in 0.1 M phosphate-
buffered 1.2% glutaraldehyde, postfixed in 1%
osmium tetroxide and embedded in Epon resin. Ultra-
thin sections were cut, double stained with uranyl ace-
tate and lead citrate, and examined with a Phillips
Morgagni electron microscope. Thickening of glo-
merular basement membrane was determined as de-
scribed [38]. Briefly, glomerular capillary loops were
photographed by electron microscopy and printed to
an original magnification of 30,000. Regions of the
basement membrane were selected at random in glo-
meruli and the thickness of each region was measured.MSC. C57BL/6 adult male mice were injected either with 0.1 M citrate
ter STZ injection, blood glucose level was determined in venous blood
in morning spot urine samples (B); blood insulin level was determined
in excretion was determined in morning spot urine samples according
(D); and renal histology was studied in serial 4-mm PAS-stained sections,
ures (E). Quantitative data shown correspond to the mean6SEM of 10
25 sections per animal, for 4 animals per experimental group. Only sig-
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Immunohistofluorescence
Deparaffinized pancreatic sections were incubated
for 2 hours with chicken antihuman insulin from
Chemicon (Temecula, CA) and rabbit antiporcine glu-
cagon from DAKO (Carpinteria, CA). After washing,
the sections were incubated for 1 hour with Alexa
594 conjugated antichicken IgG and Alexa 488 conju-
gated antirabbit IgG from Molecular Probes (Eugene,
OR). Crossreactivity of secondary antibodies was
tested by replacing the target primary antibody with
normal serum. Slices were examined under laser scan-
ning confocal microscope and 1-mm optical sections
were analyzed [39].
Donor MSCGFP Detection in Recipient Organs
Seven and 90 days after MSCGFP administration to
DM or to normal nondiabetic mice, kidneys, BM, and
heart were obtained from sacrificed animals, weighted
and washed twice with ice-cold PBS. Organs were
chopped and digested with 2 mg/mL collagenase
type II (Gibco, Auckland, NZ), 30 min at 37C. Cell
suspension thus obtained was filtered through a 100-
mm strainer and washed twice with ice-cold PBS.
High autofluorescence of kidney cells impairs GFP de-
tection [40,41]. Hence, to ensure MSCGFP recogni-
tion, isolated cells were resuspended, fixed,
permeabilized with BD Cytofix/Cytoperm kit (BDFigure 3. Characterization of bone marrow-derived MSC isolated from C57
containing 10% selected fetal bovine serum into plastic dishes. Plastic adhere
(B) or osteogenic (C) lineages. Cells were also immunophenotyped accordin
CD4, and CD8 antigens (D). Data shown are representative of cells isolated fBiosciences), and resuspended in 1 mL of PBS with
2% fetal bovine serum plus 0.5 mL of undiluted anti-
body anti-GFP Alexa Fluor 647 (Molecular Probes).
After 24 hours of incubation at 4C, the cells were
washed, filtered through a 30-mm mesh, and acquired
in a CyAn ADP flow cytometer (DakoCytomation)
as described for lymphocyte homing studies [42,43].
Data were analyzed with Summit v4.3 software, and
criteria used to consider an event as an MSCGFP
were FSC and SSC similar to ex vivo expanded MSC
and positive fluorescence, both in FL1 (GFP) and
FL8 (anti GFP-Alexa Fluor 647) channels. For each
organ, acquisition was performed up to the detection
of 100 events that fulfilled the criteria of an MSCGFP.
In the case of organs where donorMSCwere undetect-
able, a total of 500,000 events were acquired. The fre-
quency of donor MSC was expressed as the number of
MSCGFP detected in 1 organ. This technique was
validated by ex vivo injecting 1000 MSCGFP to the
kidney, BM, and heart. The recovery of MSCGFP
was 90% to 99%.Statistical Analysis
Data are presented as mean6SEM. Multiple com-
parisons between groups were performed using analy-
sis of variance (ANOVA), followed by a Bomferroni
multiple comparison test, and values of P\ .05 were
considered statistically significant. All analyses wereBL/6 adult male mice. Bone marrow cells were cultured in alpha-MEM
nt cells were ex vivo expanded (A) and differentiated into adipogenic
g to the expression of SCA-1 and CD90, and no-expression of B220,
rom 4 different animals.
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San Diego, CA).RESULTS
In the present work, nonimmunologic severe dia-
betes was induced in C57BL/6 mice by the injection
of a single dose of 200 mg/kg STZ, a protocol that
causes rapid and massive b-pancreatic cell destruction.
Mice thus generated (DMmice) weremaintainedwith-
out insulin treatment to allow for the progression of se-
vere diabetes and the appearance of its complications.
At day 30 post-STZ injection, blood glucose levels
of DMmice increased from normal values (15665mg/
dL) to severe hyperglycemia (482619 mg/dL)
(Figure 2A). Together, in DM mice glycosuria was
130 times higher (13,0006600 versus 100610 mg/
dL) and blood insulin values were 3 times lower than
those in normal nondiabetic animals (0.2660.03 ver-
sus 0.9660.11 mg/L) (Figure 2B and C).
STZ, when used at high doses, has a modest neph-
rotoxic effect [44]. Accordingly, 7 days post-STZ
injection, a discrete increase in albuminuria was
observed (2763 U-Alb mg/U-Crea mg) (Figure 2D).
However, this level did not change up to 30 days
(Figure 2D) and did not associate with any glomerular
or tubular histopathologic alterations (Figure 2E).
Thus, it was considered as a baseline.
At day 30 post-STZ injection, animals were ran-
domly assigned into 2 groups: untreated DM mice
received the vehicle and MSC-treated DM mice
received 2 doses (day 30 and 51) of 0.5106 BM-derivedFigure 4. Prevention of renal failure in MSC-treated DMmice: functional data
plasma (untreated) or 0.5106 MSC resuspended in 0.2 mL of 5% mice plasma
injection, urinary albumin excretion was determined in morning spot urine sam
sessed by commercial kits. Data shown correspond to the mean6SEM of 8 anMSC (Figure 1) that have been ex vivo expanded and
characterized according to their plastic adherence, mes-
enchymatic differentiation potential, and immunophe-
notype (Figure 3). During the study period, 35% (7/20)
of untreated DMmice and 25% (5/20) of MSC-treated
DM mice died or had to be killed because of severe
weight loss and cachexia. These animals were excluded
from data analysis.
As seen in Figure 4, untreated DM mice gradually
increased albumin excretion rate. Four months after
diabetes onset, they reached values 15 times higher
than that of age matched normal nondiabetic animals
(124631 veresus 861 U-Alb mg/U-Crea mg). In con-
trast,MSC-treated diabeticmicemaintained low levels
of albuminuria up to the end of the study period (2767
U-Alb mg/U-Crea mg).
When kidney weight to body weight ratio was cal-
culated, a 2-fold increase on it was observed in DM
mice compared to normal nondiabetic mice (1464
mg/g versus 6.460.4 mg/g, respectively). No signifi-
cant change was associated with MSC administration
(1365 mg/g). However, kidney function protection
achieved by MSC administration into DM mice
correlated with renal structure preservation. By light
microscopy, we observed glomerular sclerosis (Fig-
ure 5C), mesangial expansion (Figure 5E), marked tu-
bular dilatation (Figure 5D), and proteins cylinders
(Figure 5F) in untreated DM mice. However, in
MSC-treated DM mice glomeruli appeared normal
(Figure 5 G) and some tubules showed only minor
dilatation (Figure 5H), when compared to that of nor-
mal nondiabetic mice (Figure 5A and B). MSC admin-
istration was associated with a small percentage of. Thirty and 51 days after STZ injection, mice received 0.2 mL of 5% mice
(MSC treated) via the tail vein. At day 30, 50, 80, 100, and 120 post-STZ
ples according to albumin to creatinine concentrations, which were as-
imals per experimental group. Only significant P values are shown.
Figure 5. Prevention of renal failure in MSC-treated DMmice: structural data. Thirty and 51 days after STZ injection, mice received 0.2 mL of 5% mice
plasma (untreated) or 0.5106 MSC resuspended in 0.2 mL of 5% mice plasma (MSC treated) via the tail vein. One hundred twenty days post-STZ in-
jection, renal histology was studied in serial 4-mm PAS-stained sections, observed under light microscopy and focusing on glomeruli and tubule struc-
tures. Normal nondiabetic animals glomeruli (A) and tubules (B). Untreated DM mice glomerular sclerosis (C), glomerular mesangial expansion (E),
tubular dilatation (D), and tubular protein cylinders (F). MSC-treated DM mice glomeruli (G), and tubules (H). Glomerular and tubular damage quan-
tification in untreated and MSC-treated DM mice (I). Data shown are representative of 25 sections per animal and correspond to the mean6SEM of 4
animals per experimental group. Only significant P values are shown.
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lar damage (Figure 5I). Electron microscopy analysis
of kidneys of untreated DM mice revealed regions of
mesangial expansion and podocyte loss in the glomer-
ular structures (Figure 6C) and cytoplasmic vacuoles in
tubular cells (Figure 6D). However, kidneys of MSC-
treated DM mice (Figure 6E and F) showed glomeru-
lar and tubular ultrastructures similar to those of
normal nondiabetic animals (Figure 6A and B). Glo-
merular basement membrane thickening was unde-
tectable in all studied animals.
To find out if renoprotection observed after MSC
transplantation into severe nonimmunologically in-
duced diabetic mice was secondary to a concomitant
improvement of endocrine pancreas function, glyce-
mia was determined throughout the study period.
Five days post-STZ injection, DM mice reached
hyperglycemic value (480613 mg/dL) and continuedFigure 6. Prevention of renal failure in MSC-treated DM mice: ultrastructural
mice plasma (untreated) or 0.5106 MSC resuspended in 0.2 mL of 5% mice pl
injection, renal histology was studied in ultrathin sections, observed under elect
nondiabetic animals glomeruli (A) and tubules (B). Untreated DM mice glomer
oplasmic vacuole (D). MSC-treated DM mice glomeruli (E) and tubules (F). Da
experimental group.with elevated blood glucose levels until the end of
the study, independently if they received or not
MSC (421623 versus 457632 mg/dL) (Figure 7A).
Accordingly, untreated and MSC-treated DM mice
exhibited very low insulinemia compared to normal
nondiabetic animals (0.2860.02 versus 0.9660.11
mg/L) (Figure 7B). At the histologic level, b-pancreatic
islets were less abundant in untreated and MSC-
treated DM mice than in normal nondiabetic animals
(961 versus 2764 islet/section) (Figure 7C). Further-
more, the remnant islets were architecturally altered,
showing rare insulin producing cells and a massive
expansion of glucagon producing cells (Figure 7D).
Thus, in contrast to what we have previously
reported in an immunologically induced diabetes
model [25], in this nonimmunologically induced dia-
betes model, MSC administration did not improves
diabetes condition.data. Thirty and 51 days after STZ injection, mice received 0.2 mL of 5%
asma (MSC treated) via the tail vein. One hundred twenty days post-STZ
ronmicroscopy and focusing on glomeruli and tubule structures. Normal
ural mesangial expansion and podocyte lost (C) and tubular cell with cit-
ta shown are representative of 10 sections per animal, for 4 animals per
Figure 7. No improvement of endocrine pancreas function in MSC-treated DMmice. Thirty days and 51 days post-STZ injection, mice received 0.2 mL
of 5%mice plasma (untreated) or 0.5106 MSC resuspended in 0.2mL of 5%mice plasma (MSC treated) via the tail vein. Every 3 days, blood glucose level
was determined in alert nonfasted animals using the Accu-Chek Go system (A). One hundred twenty days post-STZ injection, blood insulin level was
determined in venous blood samples obtained from alert fasted animals (B); b-pancreatic islets were quantified in serial 4-mm hematoxilin/eosin-stained
sections, observed under light microscopy (C); b-pancreatic islets were characterized by immunohistofluorescence according to the presence and dis-
tribution of insulin- and glucagon-producing cells (red and green, respectively) (D). Quantitative data shown correspond to the mean6SEM of 8 animals
per experimental group. Qualitative data shown are representative of 25 sections per animal, for 4 animals per experimental group.
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immunologically induced diabetic mice was assessed
and compared to normal nondiabetic mice. Donor
MSC were found into the kidney and the BM of DM
mice 7 days postadministration (Figure 8A). However
MSCGFP were undetectable in any of the tested organs
obtained from normal nondiabetic mice (Figure 8B).
Eventhough there was a significant interanimal vari-
ability in the amount of MSCGFP detected in DM
mice (Figure 8C), data appear to be reliable because
negative organs were always negative (e.g., heart) and
relative abundance of donor cells was maintained
across organ types for a fixed time (e.g., 90 days after
MSCGFP administration into DM mice, the BM is
the organ with highest frequency of donor cells in all
animal tested).
Thus, a small number of donor cells homed (day 7)
and persisted (day 90) both in the kidney and the BMof
DM mice (Figure 8C).DISCUSSION
Hyperglycemia is a major risk factor for DN [7],
but other features like glycation end-products and
overexpression of different growth factors are alsoassociated with its pathogenesis [16]. Extracellular
matrix accumulation is one of the hallmarks in the de-
velopment of the disease that leads to the formation of
glomerular and interstitial lesions [15]. Recent studies
suggest that inflammatory processes and immune cells
might be involved in the development and progression
of DN [45]. Thus, macrophages, neutrophils, and T
lymphocyte migration and activation into the kidney,
maintain a chronic inflammatory process that is crucial
for parenchyma and vascular injury. Although, the kid-
ney possesses a remarkable regenerative capacity [46],
the persistent presence of former noxas results in renal
failure in diabetic individuals. Thus, an ideal therapeu-
tic strategy for DN might contribute to kidney regen-
eration through the replenishment of renal cells and/
or managing pathogenic factors. Here, we show that
endovenous administration of syngeneic MSC pre-
vents renal failure in diabetic mice eventhough there
was no improvement in diabetes condition.
Previously we reported that systemic administra-
tion of MSC into immunologically induced type 1 di-
abetic mice reduced microalbuminuria and preserved
normal renal histology [25]. By contrast, untreated
type 1 diabetic mice developed the early harbingers
of DN (mild microalbuminuria and tubular and glo-
merular hyalinosis). In that work, renal protection
Figure 8. Donor MSCGFP were detected in the kidney and bone marrow of DM mice, but not in normal nondiabetic mice. A half million of MSCGFP
resuspended in 0.2 mL of 5%mice plasmawere administered via the tail vein to receptors. Seven days later, the presence of donor cells into kidneys, bone
marrow, and heart of DMmice (A) or normal nondiabetic mice (B) was assessed by flow cytometry. Events that appear in gate shownwere considered as
MSCGFP. Plots are representative data for organs obtained from 4DMmice and 4 normal nondiabetic mice. The absolute numbers of donor cells found in
kidney and bone marrow of DM mice, 7 and 90 days after MSCGFP administration were expressed as the mean6SEM of data obtained for 4 animals per
time (C).
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because of the functional recovery of insulin-
producing cells and the regeneration of b-pancreatic
structures. In contrast, in the nonimmunologically
induced diabetes model, MSC administration reverted
neither hyperglycemia nor hypoinsulinemia, suggest-
ing that the contribution of transplanted MSC to b-
pancreatic cell regeneration depends on the etiology
of diabetes; that is, on the mechanism by which b-
pancreatic cells have been destroyed. Interestingly,
even if hyperglycemia remains high, renal failure did
not progress in MSC-treated DM mice, although in
untreated DM mice, microalbuminuria gradually
increased, and at the end of the study renal histopath-
ologic alterations were evident.
To determine whether renoprotection associated
with MSC administration is related to the recruitment
of donor cells into the kidneys, we evaluated the bio-
distribution of MSCGFP once administered in DM
mice. One week or 3 months after administration, do-
nor cells were found in the kidney of DM mice
(2266102 and 3746120 donor cells/kidney, respec-
tively). MSCGFP were also found in the BM but notin the heart of DM mice. On the other hand, donor
MSC neither home nor persist in any tested organ of
normal nondiabetic mice, suggesting that signals pro-
duced by damage tissues are required for MSC lodg-
ment into the organs of DM mice [47]. The small
number of donor cells detected in the kidneys of dia-
betic receptor either 7 or 90 days postadministration
indicates a discrete renotropism of MSC, and make
hard to explain the observed beneficial effect in kidneys
of diabetic mice through a differentiation mechanism,
as has been described in some acute renal damage
models [48,49]. Accordingly, recently it has been
shown that the major cell source for kidney
regeneration and homeostasis are the intrarenal cells
[40,41].
Rare donor cells that persist in the kidney of dia-
betic animals might have a therapeutic effect because
of their ability to produce renotrophic factors or
anti-inflammatory cytokines [50-52]. For instance, it
is already known that MSC secrete hepatocyte growth
factor, vascular endothelial growth factor, and bone
morphogenic factors, which promote mitogenic, anti-
apoptotic, and morphogenic activities of intrarenal
1364 Biol Blood Marrow Transplant 15:1354-1365, 2009F. Ezquer et al.cells [53-55]. MSC also produce IL-10, which gener-
ates a protective microenvironment that might avoid
the immunologic destruction of renal cells [53]. On
the other hand, MSCs might contribute to the remod-
eling of the extracellular matrix, and hence, abrogate
renal structural damage [56]. Currently, we are study-
ing the relative contribution of those potential mecha-
nisms in renoprotection observed after systemic
administration of MSC into DM mice.
Our preclinical results support endovenous admin-
istration of MSC as a cell therapy strategy that, with-
out recipient preconditioning, will prevent chronic
renal diseases secondary to diabetes even if hyperglyce-
mia condition remains uncorrected.ACKNOWLEDGMENTS
The authors thank Mrs. Micaela Ricca for assis-
tance with animal care and Mrs. Carolina Larrain for
English editing of the manuscript. This work was sup-
ported by grants PBCTPSD-34 to P.C. and FONDE-
CYT No. 1051057 to A.Y.
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Zimmet P, Alberti KG, Shaw J. Global and societal implications
of the diabetes epidemic. Nature. 2001;414:782-787.
2. Wild S, Roglic G,Green A, Sicree R, KingH.Global prevalence
of diabetes: estimates for the year 2000 and projections for 2030.
Diabetes Care. 2004;27:1047-1053.
3. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice.
Nephropathy in patients with type 2 diabetes. N Engl J Med.
2002;346:1145-1151.
4. USRDS. The United States Renal Data System. Am J Kidney
Dis. 2003;42:1-230.
5. Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of pri-
mary renal diseases leading to end-stage renal failure in the
United States, Europe, and Australia/New Zealand: results
from an international comparative study. Am J Kidney Dis.
2000;35:157-165.
6. ChaversBM,BilousRW,EllisEN,SteffesMW,Mauer SM.Glo-
merular lesions and urinary albumin excretion in type I diabetes
without overt proteinuria. N Engl J Med. 1989;320:966-970.
7. Cooper ME. Pathogenesis, prevention, and treatment of dia-
betic nephropathy. Lancet. 1998;352:213-219.
8. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic
nephropathy. J Am Soc Nephrol. 2005;16:S30-S33.
9. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortal-
ity in all patients on dialysis, patients on dialysis awaiting trans-
plantation, and recipients of a first cadaveric transplant.NEngl J
Med. 1999;341:1725-1730.
10. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R,
HanedaM. Effects of antioxidants in diabetes-induced oxidative
stress in the glomeruli of diabetic rats. J Am Soc Nephrol. 2003;
14:S250-S253.
11. Kim YH, Goyal M, Kurnit D, et al. Podocyte depletion and glo-
merulosclerosis have a direct relationship in the PAN-treated
rat. Kidney Int. 2001;60:957-968.
12. Siu B, Saha J, SmoyerWE, Sullivan KA, Brosius FC. Reduction
in podocyte density as a pathologic feature in early diabeticnephropathy in rodents: prevention by lipoic acid treatment.
BMC Nephrol. 2006;7:6.
13. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ,
Tesch GH. Monocyte chemoattractant protein-1 promotes the
development of diabetic renal injury in streptozotocin-treated
mice. Kidney Int. 2006;69:73-80.
14. Furuta T, Saito T, Ootaka T, et al. The role of macrophages in
diabetic glomerulosclerosis. Am J Kidney Dis. 1993;21:480-485.
15. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH.Macro-
phages in streptozotocin-induced diabetic nephropathy: poten-
tial role in renal fibrosis. Nephrol Dial Transplant. 2004;19:
2987-2996.
16. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC,
Tesch GH. Intercellular adhesion molecule-1 deficiency is pro-
tective against nephropathy in type 2 diabetic db/db mice. J Am
Soc Nephrol. 2005;16:1711-1722.
17. Rodby RA, Rohde R, Evans J, Bain RP, MulcahyWS, Lewis EJ.
The study of the effect of intensity of blood pressure manage-
ment on the progression of type 1 diabetic nephropathy: study
design and baseline patient characteristics. Collaborative Study
Group. J Am Soc Nephrol. 1995;5:1775-1781.
18. Dressler RL. Antihypertensive agents for prevention of diabetic
nephropathy. Am Fam Physician. 2006;74:77-79.
19. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mecha-
nisms of diabetic nephropathy and its therapeutic intervention.
Curr Drug Targets. 2007;8:952-959.
20. Caplan AI. The mesengenic process. Clin Plast Surg. 1994;21:
429-435.
21. Herrera MB, Bussolati B, Bruno S, Fonsato V, Romanazzi GM,
Camussi G. Mesenchymal stem cells contribute to the renal
repair of acute tubular epithelial injury. Int J Mol Med. 2004;
14:1035-1041.
22. Fang TC, Alison MR, Cook HT, Jeffery R, Wright NA,
Poulsom R. Proliferation of bone marrow-derived cells contrib-
utes to regeneration after folic acid-induced acute tubular injury.
J Am Soc Nephrol. 2005;16:1723-1732.
23. Wong CY, Cheong SK, Mok PL, Leong CF. Differentiation of
human mesenchymal stem cells into mesangial cells in post-
glomerular injury murine model. Pathology. 2008;40:52-57.
24. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D,
Kalluri R. Bone-marrow-derived stem cells repair basement
membrane collagen defects and reverse genetic kidney disease.
Proc Natl Acad Sci USA. 2006;103:7321-7326.
25. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ,
Conget PA. Systemic administration of multipotent mesenchy-
mal stromal cells reverts hyperglycemia and prevents nephropa-
thy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;
14:631-640.
26. Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells
from human marrow home to and promote repair of pancreatic
islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl
Acad Sci USA. 2006;103:17438-17443.
27. Katoh M, Ohmachi Y, Kurosawa Y, Yoneda H, Tanaka N,
Narita H. Effects of imidapril and captopril on streptozotocin-
induced diabetic nephropathy in mice. Eur J Pharmacol. 2000;
398:381-387.
28. Grover JK, Vats V, Rathi SS, Dawar R. Traditional Indian anti-
diabetic plants attenuate progression of renal damage in strepto-
zotocin induced diabetic mice. J Ethnopharmacol. 2001;76:
233-238.
29. Thirone AC, Scarlett JA, Gasparetti AL, et al. Modulation of
growth hormone signal transduction in kidneys of streptozotocin-
induced diabetic animals: effect of a growth hormone receptor an-
tagonist.Diabetes. 2002;51:2270-2281.
30. Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion
molecule-1-deficient mice are resistant against renal injury after
induction of diabetes. Diabetes. 2003;52:2586-2593.
31. Gabra BH, Sirois P. Beneficial effect of chronic treatment with
the selective bradykinin B1 receptor antagonists, R-715 and
R-954, in attenuating streptozotocin-diabetic thermal hyperal-
gesia in mice. Peptides. 2003;24:1131-1139.
Biol Blood Marrow Transplant 15:1354-1365, 2009 1365MSC Administration Prevents Diabetic Renal Failure32. Dogrul A, Gul H, Yildiz O, Bilgin F, Guzeldemir ME. Canna-
binoids blocks tactile allodynia in diabetic mice without attenu-
ation of its antinociceptive effect. Neurosci Lett. 2004;368:82-86.
33. Conget PA, Minguell JJ. Phenotypical and functional properties
of human bone marrow mesenchymal progenitor cells. J Cell
Physiol. 1999;18:67-73.
34. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for
defining multipotent mesenchymal stromal cells. The Interna-
tional Society for Cellular Therapy position statement.Cytother-
apy. 2006;8:315-317.
35. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived
stromal cells express genes encoding a broad spectrum of
arteriogenic cytokines and promote in vitro and in vivo arterio-
genesis through paracrine mechanisms. Circ Res. 2004;94:
678-685.
36. Wakasugi S, Maeda S, Shimada K, et al. Structural comparisons
between mouse and human prealbumin. J Biochem. 1985;98:
1707-1714.
37. Benigni A, Zoja C, Zatelli C, et al. Vasopeptidase inhibitor
restores the balance of vasoactives hormones in progressive
nephropathy. Kidney Int. 2004;66:1959-1965.
38. Hayakawa M, Shibata M. The in vitro and in vivo inhibition of
protein glycosylation and diabetic vascular basement membrane
thickening by pyridoxal-50-phosphate. J Nutr Sci Vitaminol
(Tokyo). 1991;37:149-159.
39. Yanez AJ, Bertinat R, Spichiger C, et al. Novel expression of
liver FBPase in Langerhans islets of human and rat pancreas.
J Cell Physiol. 2005;205:19-24.
40. Duffield JS, Park KM, Hsiao LL, et al. Restoration of tubular
epithelial cells during repair of the postischemic kidney occurs
independently of bone marrow-derived stem cells. J Clin Invest.
2005;115:1743-1755.
41. Lin F, Moran A, Igarashi P. Intrarenal cells, not bone marrow-
derived cells, are the major source for regeneration in postische-
mic kidney. J Clin Invest. 2005;115:1756-1764.
42. Li R, Perez N, Karumuthil-Melethil S, Vasu C. Bone marrow is
a preferential homing site for autoreactive T-cells in type 1 dia-
betes. Diabetes. 2007;56:2251-2259.
43. Allers K, Kunkel D, Moos V, et al. Migration patterns of non-
specifically activated versus nonactivated nonhuman primate Tlymphocytes: preferential homing of activated autologous CD8
1 T cells in the rectal mucosa. J Immunother. 2008;31:334-344.
44. TayYC,WangY,Kairaitis L, RanganGK,ZhangC,HarrisDC.
Can murine diabetic nephropathy be separated from superim-
posed acute renal failure? Kidney Int. 2005;68:391-398.
45. Galkina E, Ley K. Leukocyte recruitment and vascular injury in
diabetic nephropathy. J Am Soc Nephrol. 2006;17:368-377.
46. Liu KD, Brakeman PR. Renal repair and recovery. Crit Care
Med. 2008;36:S187-S192.
47. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in
health and disease. Nat Rev Immunol. 2008;8:726-736.
48. Imasawa T, Utsunomiya Y, Kawamura T, et al. The potential of
bonemarrow-derived cells to differentiate to glomerular mesan-
gial cells. J Am Soc Nephrol. 2001;12:1401-1409.
49. Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are
renotropic, helping to repair the kidney and improve function in
acute renal failure. J Am Soc Nephrol. 2004;15:1794-1804.
50. Semedo P, Palasio CG, Oliveira CD, et al. Early modulation of
inflammation by mesenchymal stem cell after acute kidney
injury. Int Immunopharmacol. 2009 [Epub ahead of print].
51. Le Blanc K. Mesenchymal stromal cells: tissue repair and im-
mune modulation. Cytotherapy. 2006;8:559-561.
52. McTaggart SJ, Atkinson K. Mesenchymal stem cells: immu-
nobiology and therapeutic potential in kidney disease. Nephrol-
ogy. 2007;12:44-52.
53. Togel F, Hu Z,Weiss K, Isaac J, Lange C,Westenfelder C. Ad-
ministered mesenchymal stem cells protect against ischemic
acute renal failure through differentiation-independent mecha-
nisms. Am J Physiol Renal Physiol. 2005;289:F31-F42.
54. Togel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C.
Vasculotropic, paracrine actions of infused mesenchymal stem
cells are important to the recovery from acute kidney injury.
Am J Physiol Renal Physiol. 2007;292:F1626-F1635.
55. Semedo P, Wang PM, Andreucci TH, et al. Mesenchymal stem
cells ameliorate tissue damages triggered by renal ischemia and
reperfusion injury. Transplant Proc. 2007;39:421-423.
56. Higashiyama R, Inagaki Y, Hong YY, et al. Bone marrow-
derived cells express matrix metalloproteinases and contribute
to regression of liver fibrosis in mice. Hepatology. 2007;45:
213-222.
